| 1 |
34312098 | Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. | 2022 Jan |
2 |
| 2 |
34753632 | A Retrospective Analysis of Metronomic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Versus Docetaxel and Cyclophosphamide (TC) as Adjuvant Treatment in Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer. | 2022 Apr |
1 |
| 3 |
35101364 | Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. | 2022 Jun |
1 |
| 4 |
35385034 | Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer. | 2022 Apr 4 |
1 |
| 5 |
35531104 | Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial. | 2022 Apr |
1 |
| 6 |
33966140 | High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer. | 2021 Nov |
1 |
| 7 |
34268990 | Sequential anthracycline and weekly paclitaxel might be more effective compared to docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients. | 2021 May-Jun |
1 |
| 8 |
34699004 | Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers. | 2021 Dec |
1 |
| 9 |
31776320 | Capecitabine + Epirubicin + Cyclophosphamide Combination Therapy (CEX Therapy) as Neoadjuvant Chemotherapy for HER-2-Negative Breast Cancer: A Retrospective, Single-Center Study. | 2020 May 15 |
2 |
| 10 |
31821506 | Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. | 2020 Jan 24 |
1 |
| 11 |
31883395 | Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype. | 2020 May |
2 |
| 12 |
32211111 | Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy. | 2020 |
2 |
| 13 |
32461977 | Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study. | 2020 |
1 |
| 14 |
30785826 | West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. | 2019 Apr 1 |
1 |
| 15 |
30952749 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial. | 2019 Apr |
1 |
| 16 |
29433963 | Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. | 2018 Mar |
2 |
| 17 |
30570890 | Adding anthracycline plus cyclophosphamide to adjuvant paclitaxel plus trastuzumab might be more reasonable in stage I hormone receptor negative HER-2 positive breast cancer patients. | 2018 Sep-Oct |
1 |
| 18 |
30687062 | Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease. | 2018 Sep-Dec |
1 |
| 19 |
26754092 | Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer. | 2017 Jan |
3 |
| 20 |
28167568 | Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. | 2017 Feb |
1 |
| 21 |
28361910 | Her-2 expression regulated by downregulation of miR-9 and which affects chemotherapeutic effect in breast cancer. | 2017 May |
1 |
| 22 |
28101033 | Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin. | 2016 Sep-Dec |
1 |
| 23 |
28174484 | Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study. | 2016 Dec |
2 |
| 24 |
26162690 | Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302). | 2015 Sep |
1 |
| 25 |
25116755 | A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. | 2014 Oct |
1 |
| 26 |
25332249 | Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. | 2014 Nov 20 |
1 |
| 27 |
25548584 | Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer. | 2014 Dec |
1 |
| 28 |
24007746 | Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. | 2013 Oct |
2 |
| 29 |
22526409 | Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. | 2012 Aug |
1 |
| 30 |
21189395 | Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. | 2011 Mar 1 |
1 |
| 31 |
21421542 | Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. | 2011 Dec |
1 |
| 32 |
21788566 | Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. | 2011 Sep 1 |
2 |
| 33 |
21918347 | [A case of effective combination therapy with docetaxel, cyclophosphamide and trastuzumab as primary systemic therapy for locally advanced HER2-positive breast cancer]. | 2011 Sep |
1 |
| 34 |
19526361 | Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. | 2010 Feb |
1 |
| 35 |
20133257 | Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. | 2010 Feb |
1 |
| 36 |
20332474 | Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer. | 2010 Feb |
1 |
| 37 |
21160270 | [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. | 2010 Dec |
1 |
| 38 |
21188112 | Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients. | 2010 Aug 20 |
2 |
| 39 |
19470942 | Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. | 2009 Jul 20 |
1 |
| 40 |
19620488 | Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. | 2009 Aug 20 |
1 |
| 41 |
19805669 | Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. | 2009 Dec 10 |
4 |
| 42 |
19825954 | Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. | 2009 Oct 15 |
2 |
| 43 |
21319009 | Combination therapy by trastuzumab with 5'-deoxy-5-fluorouridine and cyclophosphamide in patients with metastatic breast cancer. | 2009 Sep 20 |
1 |
| 44 |
18390970 | Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. | 2008 May 10 |
3 |
| 45 |
17010609 | Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. | 2007 Feb |
1 |
| 46 |
17063267 | Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. | 2007 Jul |
1 |
| 47 |
17200359 | Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. | 2007 Jan 1 |
1 |
| 48 |
17296975 | Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. | 2007 Apr 1 |
1 |
| 49 |
17449250 | The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. | 2007 Jun |
1 |
| 50 |
17647266 | Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. | 2007 Sep 15 |
1 |